HALB — Halberd Share Price
- $1.40m
- $3.34m
- $0.30m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 4.97 | ||
EV to EBITDA | 34.77 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 13.11% | ||
Return on Equity | n/a | ||
Operating Margin | 34.12% |
Financial Summary
Year End 31st Jul | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.01 | 0.01 | 0.03 | 0.08 | 0.3 | n/a | n/a | 155.33% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents, and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s subsidiaries include Alaric Corporation, and Extendalife, Inc.
Directors
- Last Annual
- July 31st, 2012
- Last Interim
- January 31st, 2013
- Incorporated
- March 27th, 2020
- Public Since
- June 12th, 2009
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 635,874,842

- Address
- P.O. Box 25, JACKSON CENTER, 16133
- Web
- https://halberdcorporation.com/
- Phone
- Auditors
- Rehmann Robson, P.C.
Similar to HALB
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 21:01 UTC, shares in Halberd are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Halberd last closed at $0.00 and the price had moved by -73.81% over the past 365 days. In terms of relative price strength the Halberd share price has underperformed the S&P500 Index by -75.71% over the past year.
There is no consensus recommendation for this security.
Find out moreHalberd does not currently pay a dividend.
Halberd does not currently pay a dividend.
Halberd does not currently pay a dividend.
To buy shares in Halberd you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Halberd had a market capitalisation of $1.40m.
Here are the trading details for Halberd:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: HALB
Based on an overall assessment of its quality, value and momentum Halberd is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Halberd. Over the past six months, its share price has underperformed the S&P500 Index by -50.98%.
As of the last closing price of $0.00, shares in Halberd were trading -46.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Halberd PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Halberd's directors